Deal Announcements

TargeGen Closes $40 Million Fourth Round

Friday, July 13, 2007 5:00:00 AM PDT | VentureDeal Staff

SAN DIEGO, CA -- Pharmaceutical company TargeGen, Inc. said that it closed its series D round of financing, receiving $40 million.

The company is currently in Phase II clinical trials for its topical treatment for macular degeneration, diabetic macular edema and diabetic retinopathy.  TargeGen is also developing treatments for myelofibrosis.

Investors included Innovis Investments, VantagePoint Venture Partners, CTI Life Sciences Fund, Forward Ventures, Enterprise Partners, Chicago Growth Partners/William Blair Capital Partners, CDP Capital,  BB Biotech, Hambrecht & Quist Capital Management, Pappas Ventures and others.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1